dc.creatorSPOSITO, Andrei C.
dc.creatorRAMIRES, Jose A. F.
dc.creatorJUKEMA, J. Wouter
dc.creatorMOLINA, Juan Carlos
dc.creatorSILVA, Pedro Marques da
dc.creatorGHADANFAR, Mathieu M.
dc.creatorWILSON, Peter W. F.
dc.date.accessioned2012-10-19T17:17:38Z
dc.date.accessioned2018-07-04T15:06:10Z
dc.date.available2012-10-19T17:17:38Z
dc.date.available2018-07-04T15:06:10Z
dc.date.created2012-10-19T17:17:38Z
dc.date.issued2009
dc.identifierCURRENT MEDICAL RESEARCH AND OPINION, v.25, n.5, p.1171-1178, 2009
dc.identifier0300-7995
dc.identifierhttp://producao.usp.br/handle/BDPI/21837
dc.identifier10.1185/03007990902846423
dc.identifierhttp://dx.doi.org/10.1185/03007990902846423
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1618611
dc.description.abstractObjective: To evaluate physicians` attitudes and adherence to the use of risk scores in the primary prevention of cardiovascular disease (CVD). Design and methods: A cross-sectional survey of 2056 physicians involved in the primary prevention of CVD. Participants included cardiologists (47%), general practitioners (42%), and endocrinologists (11%) from several geographical regions: Brazil (n=968), USA (n=381), Greece (n=275), Chile (n=157), Venezuela (n=128), Portugal (n=42), The Netherlands (n=41), and Central America (Costa Rica, Panama, El Salvador and Guatemala; n=64). Results: The main outcome measure was the percentage of responses on a multiple-choice questionnaire describing a hypothetical asymptomatic patient at intermediate risk for CVD according to the Framingham Risk Score. Only 48% of respondents reported regular use of CVD risk scores to tailor preventive treatment in the case scenario. Of non-users, nearly three-quarters indicated that `It takes up too much of my time` (52%) or `I don`t believe they add value to the clinical evaluation` (21%). Only 56% of respondents indicated that they would prescribe lipid-lowering therapy for the hypothetical intermediate-risk patient. A significantly greater proportion of regular users than non-users of CVD risk scores identified the need for lipid-lowering therapy in the hypothetical patient (59 vs. 41%; p<0.0001).
dc.languageeng
dc.publisherLIBRAPHARM/INFORMA HEALTHCARE
dc.relationCurrent Medical Research and Opinion
dc.rightsCopyright LIBRAPHARM/INFORMA HEALTHCARE
dc.rightsclosedAccess
dc.subjectCardiovascular risk
dc.subjectDyslipidemia
dc.subjectLipid-lowering therapy
dc.subjectPrimary prevention
dc.titlePhysicians` attitudes and adherence to use of risk scores for primary prevention of cardiovascular disease: cross-sectional survey in three world regions
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución